Plain-English translation of NCT06876610 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are developing a new blood test that can help diagnose breast cancer by looking at special chemical markers called methylation patterns in DNA fragments found in the blood. This study collects blood and tissue samples from people with breast cancer and people with benign (non-cancerous) breast conditions to identify which methylation patterns are unique to cancer. The goal is to create a diagnostic tool that could help doctors catch breast cancer earlier.
Current breast cancer screening methods like mammograms can sometimes miss cancers or produce false alarms. A simple blood test based on DNA markers could offer a faster, less invasive way to help diagnose breast cancer and distinguish it from harmless breast conditions.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will donate a blood sample and allow researchers to collect a tissue sample from your breast biopsy or surgery. The blood draw is a standard procedure, similar to routine lab work. Your samples will be analyzed to look for the methylation markers that help distinguish cancer from benign conditions. The study involves one or two visits to collect samples; there is no long-term treatment or follow-up required.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China
Sponsor
Geneplus-Beijing Co. Ltd.
Collaborators
Chinese Academy of Medical Sciences
Enrollment target
~200 participants
Started
March 2025
Primary completion
August 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
30 Years – 75 Years
Last updated on clinicaltrials.gov in March 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.